Drugs / Hyaluronidase-oysk
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05256225 Background | Nov 2022 → Oct 2027 expected | carcinosarcoma of the corpus uteri, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma +2 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyaluronidase-oysk | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05256225 ↗ |
| Route | Subcutaneous | “trastuzumab/hyaluronidase-oysk subcutaneously (SC) over 2-5 minutes” NCT05256225 ↗ |